Bietti crystalline corneoretinal dystrophy
MONDO:0008865Bietti's crystalline dystrophy (BCD) is a rare progressive autosomal recessive tapetoretinal degeneration disease, occurring in the third decade of life, characterized by small sparkling crystalline deposits in the posterior retina and corneal limbus in addition to sclerosis of the choroidal vessels and manifesting as nightblindness, decreased vision, paracentral scotoma, and, in the end stages of the disease, legal blindness.
Also known as: BCD, Bietti crystalline corneoretinal dystrophy, Bietti crystalline retinopathy, Bietti crystalline dystrophy, Bietti tapetoretinal Degeneration with marginal corneal dystrophy
40 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
One-Time gene injection aims to halt rare eye disease
Disease control OngoingThis study tests a single injection of ZVS101e, a gene therapy that delivers a working copy of the CYP4V2 gene directly into the retina. It is for adults with Bietti's crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The trial will check wh…
Phase: PHASE1, PHASE2 • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy injection aims to restore sight in rare eye disease
Disease control OngoingThis study tests a single injection of ZVS101e gene therapy for people with Bietti's crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The therapy delivers a working copy of the CYP4V2 gene directly to the retina. Researchers will measure wh…
Phase: PHASE3 • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental gene therapy offers hope for rare blindness condition
Disease control ENROLLING_BY_INVITATIONThis study provides ZVS101e, a gene therapy, to 32 people with Bietti crystalline corneoretinal dystrophy (BCD) who were in the control group of a previous Phase III trial. The therapy uses a harmless virus to deliver a working gene to the eye, aiming to slow vision loss. The mai…
Phase: NA • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy injection aims to halt blindness from rare eye disorder
Disease control OngoingThis Phase 3 trial tests a gene therapy called VGR-R01 for Bietti crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The study will enroll 45 adults who receive either the gene therapy injection under the retina or a control treatment. Resear…
Phase: PHASE3 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Gene therapy trial aims to halt blindness from rare crystal disease
Disease control OngoingThis early-stage trial tests a gene therapy called VGR-R01 for Bietti Crystalline Dystrophy, a rare inherited eye disease that leads to progressive vision loss. The study involves 12 adults who receive the therapy via injection into the eye. The main goal is to check safety and t…
Phase: PHASE1 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Free eye tests aim to catch vision loss early in harlem and washington heights
Knowledge-focused OngoingThis study offers free vision screenings to underserved adults over 40 living in affordable housing in Harlem and Washington Heights. The goal is to find eye problems like glaucoma, cataracts, and diabetic retinopathy early and connect people with follow-up care. About 749 partic…
Phase: NA • Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC